Skip to content

    Sexual Conditions Health Center

    Font Size
    A
    A
    A

    'Female Viagra' May Treat Low Sexual Desire

    Study Shows Flibanserin Cuts Distress, Increases Satisfaction for Some Women With Low Sexual Desire
    By
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    May 18, 2010 -- Flibanserin, an antidepressant-like drug, makes sex more satisfying for some premenopausal women distressed over their low sexual desire.

    The findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).

    While HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.

    Compared to women who received inactive placebo pills, those who took flibanserin at bedtime were more likely to get relief from self-reported sexual distress, to experience more sexual desire, and to have more sexually satisfying experiences.

    The drug didn't work for all women. Just under a third of women taking flibanserin got over their sexual distress and/or lack of sexual desire (vs. about a fifth of women taking placebo pills). But the difference was important to the women, says study researcher Michael L. Krychman, MD, medical director of sexual medicine at Hoag Hospital in Newport Beach, Calif.

    "The absolute number of women who had remission of sexual distress was clinically significant, but equally important to them was how it improved their lives," Krychman tells WebMD.

    Nearly half of women taking flibanserin (and nearly a third of women taking placebo) reported at least minimal improvement in "bothersome decreased sexual desire."

    Flibanserin is taken nightly at bedtime. However, it's not an on-demand treatment. Data suggest that the drug begins to affect sexual satisfaction after four weeks of continuous treatment.

    In the 24-week "Bouquet" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects. Those most commonly reported were daytime sleepiness, dizziness, fatigue, anxiety, dry mouth, nausea, and insomnia. Some 15% of women on flibanserin, and 7% of those on placebo, stopped treatment due to side effects.

    Updated reports on data from the North American "Daisy" and "Violet" studies were made by Krychman and other researchers at this week's annual meeting of the American College of Obstetricians and Gynecologists in San Francisco.

    Kychman is an advisor to Boehringer Ingelheim and serves on their speakers' bureau, services for which he is compensated.

    1 | 2 | 3

    Today on WebMD

    couple kissing
    See pictures and get the facts.
    husband taking prescription painkillers
    13 things that can kill your sex drive.
     
    close up of cold sore
    How to stop them from spreading.
    Condom Quiz
    What are the symptoms?
     

    HIV Myth Facts
    Slideshow
    STD Overview
    Slideshow
     
    Man tearing a condom packet
    Quiz
    things your guy wish you knew slideshow
    Slideshow
     

    Thoughtful man sitting on bed
    Quiz
    Girls Puberty 10
    Quiz
     
    Couple in bed
    Article
    Young couple holding hands
    Quiz